MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock in...
$296,382K
Proceeds from issuance of
common stock in...
$14,750K
Proceeds from employee
stock option...
$3,306K
Net cash provided by
financing activities
$309,025K
Canceled cashflow
$5,413K
Net (decrease)
increase in cash, cash...
-$3,702K
Canceled cashflow
$309,025K
Stock-based compensation
$37,614K
Accounts payable
$8,238K
Interest proceeds from
maturities of zero coupon...
$2,130K
Proceeds from maturities
and sales of...
$371,739K
Proceeds from sale of
in-process research &...
$7,000K
Payment of contingent
value rights...
$5,251K
Payment of deferred
offering costs in...
$162K
Net cash used in
operating activities
-$169,252K
Canceled cashflow
$47,982K
Net cash (used in)
provided by investing...
-$143,475K
Canceled cashflow
$378,739K
Net loss
-$155,203K
Change in fair value of
derivative...
$29,769K
Prepaid expenses and
other assets
$12,819K
Gain on sale of
in-process research and...
$10,000K
Net (accretion of
discount) amortization of...
$8,090K
Accrued and other
liabilities
-$764K
Related party accounts
payable
-$589K
Purchases of marketable
securities
$522,214K
Back
Back
Cash Flow
source: myfinsight.com
Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc. (SYRE)